

Zydus Cadila registers 30% growth in sales in Q1

Ahmedabad, August 6, 2012

For the first quarter ended June 30, 2012, Zydus Cadila reported sales of Rs. 1547 crores, up by 30% from Rs. 1189 crores in the corresponding quarter of the previous year on a consolidated basis. The profit before tax, excluding one-time income, is up by 22% to Rs. 266 crores from Rs. 218 crores in the first quarter of 2011-12.

In the domestic formulations market, the company posted sales of Rs. 582 crores., up by 27 %. The company launched 30 new products, including line extensions, of which 10 products were the first to be launched in India.

During the quarter, the company's revenues were driven by 50 % y-y growth in the US business and a 37% growth in Brazil. Exports to the emerging markets grew by 84 %.

With the recent approval from the USFDA for its facility at Moraiya, the company expects to start getting new product approvals, which will further strengthen its US business. During the quarter, the company launched 3 products in Japan including one Day-1 launch. All three products have been developed and manufactured in India.

Further strengthening its regulatory pipeline, the company filed 9 ANDAs including 2 for injectible products, taking the cumulative number of US ANDA filings to 157. The company also filed 5 DMFs, taking the cumulative filings to 112 DMFs.

During the quarter, the company filed 11 new product dossiers and received 4 new product approvals for the European market, taking the cumulative approvals to 147 approvals. The company also filed 5 additional dossiers for the Brazilian market with the regulatory authority ANVISA and 3 additional dossiers with the regulatory authority COFEPRIS for Mexico.
